Correlation between Mycoplasma pneumoniae drug resistance and clinical characteristics in bronchoalveolar lavage fluid of children with refractory Mycoplasma pneumoniae pneumonia.
Alveolar lavage
Children
Drug-resistance gene mutation
Fibreoptic bronchoscopy
Refractory Mycoplasma pneumoniae pneumonia
Journal
Italian journal of pediatrics
ISSN: 1824-7288
Titre abrégé: Ital J Pediatr
Pays: England
ID NLM: 101510759
Informations de publication
Date de publication:
26 Nov 2022
26 Nov 2022
Historique:
received:
03
07
2022
accepted:
25
10
2022
entrez:
26
11
2022
pubmed:
27
11
2022
medline:
30
11
2022
Statut:
epublish
Résumé
To investigate the resistance-gene mutation of Mycoplasma pneumoniae (MP) in the bronchoalveolar lavage fluid of children with Mycoplasma pneumoniae pneumonia (MPP) and the clinical characteristics of refractory Mycoplasma pneumoniae pneumonia (RMPP) correlation. Forty-eight children with MPP were selected and placed in RMPP and non-RMPP groups based on their clinical status - whether they had worsening clinical symptoms, persistent fever and a worsening lung image. They were also separated into drug-resistance gene mutation and non-mutated groups using nucleic acid detection. The participants' data were collected on high-sensitivity C-reactive protein and MP-DNA loads, fever time, hospitalisation time, macrolide antibiotic application time and fever regression time after application. The differences in imaging manifestations were determined by using multivariate logistic regression to analyse the clinical characteristics of RMPP. Additionally, the correlation between drug-resistance gene mutations and the clinical characteristics of RMPP was summarised. Among the 48 MPP children, 31 (64.6%) had A2063G and/or A2064G gene mutation, 31 (64.6%) had RMPP and 23 (74.2%) had drug-resistance gene mutation. The children in the drug-resistance gene mutation group had higher high-sensitivity C-reactive protein and MP-DNA loads, longer fever time, hospitalisation time, macrolide antibiotic application time, fever regression time after application and extrapulmonary complications. There were more symptoms and more severe changes under bronchoscopy. The difference was statistically significant (P < 0.05). Logistic multivariate regression analysis showed that the mutation of drug-resistance genes had no significant correlation with RMPP. The mutation rate of drug-resistance genes in children with MPP is high, the inflammatory index and MP-DNA load are high, the course of the disease is long, and the changes under bronchoscopy are severe. The occurrence of RMPP is not only determined by drug-resistance genes but may also be the result of a combination of factors.
Sections du résumé
BACKGROUND
BACKGROUND
To investigate the resistance-gene mutation of Mycoplasma pneumoniae (MP) in the bronchoalveolar lavage fluid of children with Mycoplasma pneumoniae pneumonia (MPP) and the clinical characteristics of refractory Mycoplasma pneumoniae pneumonia (RMPP) correlation.
METHODS
METHODS
Forty-eight children with MPP were selected and placed in RMPP and non-RMPP groups based on their clinical status - whether they had worsening clinical symptoms, persistent fever and a worsening lung image. They were also separated into drug-resistance gene mutation and non-mutated groups using nucleic acid detection. The participants' data were collected on high-sensitivity C-reactive protein and MP-DNA loads, fever time, hospitalisation time, macrolide antibiotic application time and fever regression time after application. The differences in imaging manifestations were determined by using multivariate logistic regression to analyse the clinical characteristics of RMPP. Additionally, the correlation between drug-resistance gene mutations and the clinical characteristics of RMPP was summarised.
RESULTS
RESULTS
Among the 48 MPP children, 31 (64.6%) had A2063G and/or A2064G gene mutation, 31 (64.6%) had RMPP and 23 (74.2%) had drug-resistance gene mutation. The children in the drug-resistance gene mutation group had higher high-sensitivity C-reactive protein and MP-DNA loads, longer fever time, hospitalisation time, macrolide antibiotic application time, fever regression time after application and extrapulmonary complications. There were more symptoms and more severe changes under bronchoscopy. The difference was statistically significant (P < 0.05). Logistic multivariate regression analysis showed that the mutation of drug-resistance genes had no significant correlation with RMPP.
CONCLUSION
CONCLUSIONS
The mutation rate of drug-resistance genes in children with MPP is high, the inflammatory index and MP-DNA load are high, the course of the disease is long, and the changes under bronchoscopy are severe. The occurrence of RMPP is not only determined by drug-resistance genes but may also be the result of a combination of factors.
Identifiants
pubmed: 36435821
doi: 10.1186/s13052-022-01376-6
pii: 10.1186/s13052-022-01376-6
pmc: PMC9701416
doi:
Substances chimiques
C-Reactive Protein
9007-41-4
Anti-Bacterial Agents
0
Macrolides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
190Informations de copyright
© 2022. The Author(s).
Références
Zhongguo Dang Dai Er Ke Za Zhi. 2021 Jul;23(7):707-712
pubmed: 34266528
Diagn Microbiol Infect Dis. 2010 Aug;67(4):355-8
pubmed: 20638604
J Antimicrob Chemother. 2020 Oct 1;75(10):2752-2759
pubmed: 32653897
PLoS One. 2020 Jun 4;15(6):e0232610
pubmed: 32497137
Ital J Pediatr. 2022 May 3;48(1):64
pubmed: 35505407
Mol Med. 2019 Aug 9;25(1):38
pubmed: 31399022
Curr Med Sci. 2020 Oct;40(5):822-828
pubmed: 33123897
BMC Public Health. 2015 Feb 10;15:113
pubmed: 25879996
J Korean Med Sci. 2018 Sep 18;33(43):e268
pubmed: 30344461
Zhongguo Dang Dai Er Ke Za Zhi. 2018 Jan;20(1):37-42
pubmed: 29335080
Antimicrob Agents Chemother. 1995 Dec;39(12):2770-3
pubmed: 8593017
Microbiol Immunol. 2001;45(8):617-20
pubmed: 11592636
Zhongguo Dang Dai Er Ke Za Zhi. 2019 Feb;21(2):144-149
pubmed: 30782276
J Clin Microbiol. 2007 Nov;45(11):3534-9
pubmed: 17881549
Expert Rev Anti Infect Ther. 2018 Jan;16(1):23-34
pubmed: 29212389
Pediatrics. 2019 Oct;144(4):
pubmed: 31488697
Antimicrob Agents Chemother. 2009 May;53(5):2158-9
pubmed: 19273685